- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02288351
Intestinal Remodeling And Reprogramming of Glucose Metabolism Following Laparoscopic Roux-en-Y Gastric Bypass
The purpose of this study is to investigate small intestinal remodeling and reprogramming of glucose metabolism in patients with Type 2 Diabetes Mellitus (T2DM) who undergo laparoscopic Roux-en-Y Gastric Bypass (RYGB). Our specific goal is to determine if the gene and protein expression levels of GLUT-1 are up regulated in the Roux limb and whether this is a major mechanism for the remission of T2DM following RYGB.
The two aims of the study are: 1) to demonstrate that the basement membrane glucose transporter 1 (GLUT-1) is upregulated in the Roux limb following RYGB, and 2) to demonstrate that the upregulation of GLUT-1 is a major mechanism for the improvement in glycemic control observed in T2DM patients undergoing RYGB.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of Type 2 Diabetes Mellitus
- Age between 18 and 65 years of age
- BMI > 35kg/m²
- Diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
Exclusion Criteria:
- Patients undergoing revision from another bariatric procedure to RYGB
- Presence of a seizure disorder (GLUT-1 deficiency syndrome)
- Use of Tricyclic antidepressants
- Use of tobacco products
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: RYGB with mucosal abnormality on EGD
Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
|
Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test.
They will be asked to fast for 12 hours prior to this visit (except water).
During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes.
During this visit a catheter will be placed in a vein in their arm for blood sample collections.
A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB).
During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Elevated Glut-1 gene and protein expression levels
Tidsramme: 2 months
|
Gene and protein expression levels of GLUT-1 will be analyzed from the specimens obtained intra-operatively (baseline) and at 2 months post-operatively to determine if levels are significantly elevated above baseline.
Quantitative real-time PCR and Western blot techniques will be utilized as described in C below.
|
2 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Glut-1 level change in fasting glucose
Tidsramme: 2 months
|
Change in GLUT-1 levels will be correlated with changes in fasting glucose, mixed meal stimulation test, and homeostasis model assessment (HOMA).
Secondly, at 2 months post-operatively, whole-body positron emission tomography/computed tomography (PET/CT) scanning with Fluorodeoxyglucose (FDG) will be performed to evaluate glucose uptake and utilization in the Roux limb.
|
2 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Philip Omotosho, MD, Duke University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- Pro00054934
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Mix Nutrient Meal
-
NestléGreat Ormond Street Hospital for Children NHS Foundation TrustFullført
-
Emory UniversityCenters for Disease Control and PreventionFullført
-
Menzies Institute for Medical ResearchDeakin UniversityAktiv, ikke rekrutterende
-
Hebei Medical UniversityFullført
-
Samsung Medical CenterFullført
-
DSM Nutritional Products, Inc.RekrutteringIrritabel tarm-syndrom | IBS - Irritabel tarmsyndromIrland
-
University of LeedsFullførtOvervekt | OvervektigStorbritannia
-
Eli Lilly and CompanyFullførtDiabetes mellitus, type 2Forente stater, Canada, India, Puerto Rico, Australia, Spania, Nederland, Ungarn, Brasil, Hellas, Romania, Argentina
-
Azienda Ospedaliera Universitaria Integrata VeronaUniversita di Verona; European Foundation for the Study of DiabetesUkjentType 1 diabetes mellitusItalia
-
Chungbuk National University HospitalUkjentLipidmetabolismeforstyrrelser | Sarkopeni | Kronisk metabolsk lidelseKorea, Republikken